Carregant...
JAK2 inhibitors: are they the solution?
The discovery of the JAK2V617F mutation in patients with Philadelphia-negative myeloproliferative neoplasms (Ph-negative MPNs) started the era of targeted therapy for these diseases. Until now, patients had few treatment options available, usually restricted to hydroxyurea, interferon preparations,...
Guardat en:
| Publicat a: | Clin Lymphoma Myeloma Leuk |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2011
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4445410/ https://ncbi.nlm.nih.gov/pubmed/22035745 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2011.02.007 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|